Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
International Journal of Chronic Obstructive Pulmonary Disease

Publisher Rights Statement:
Copyright © 2010 Marwick and Chung, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease

John A Marwick 1
Kian Fan Chung 2

1 Medical Research Council Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh Medical School, Edinburgh, UK; 2 Section of Airways Disease, National Heart and Lung Institute, Imperial College London, UK

Abstract: Chronic obstructive pulmonary disease (COPD) is characterized by an abnormal and chronic inflammatory response in the lung that underlies the chronic airflow obstruction of the small airways, the inexorable decline of lung function, and the severity of the disease. The control of this inflammation remains a key strategy for treating the disease; however, there are no current anti-inflammatory treatments that are effective. Although glucocorticoids (GCs) effectively control inflammation in many diseases such as asthma, they are less effective in COPD. The molecular mechanisms that contribute to the development of this relative GC-insensitive inflammation in the lung of patients with COPD remain unclear. However, recent studies have indicated novel mechanisms and possible therapeutic strategies. One of the major mechanisms proposed is an oxidant-mediated alteration in the signaling pathways in the inflammatory cells in the lung, which may result in the impairment of repressor proteins used by the GC receptor to inhibit the transcription of proinflammatory genes. Although these studies have described mechanisms and targets by which GC function can be restored in cells from patients with COPD, more work is needed to completely elucidate these and other pathways that may be involved in order to allow for more confident therapeutic targeting. Given the relative GC-insensitive nature of the inflammation in COPD, a combination of therapies in addition to a restoration of GC function, including effective alternative anti-inflammatory targets, antioxidants, and proresolving therapeutic strategies, is likely to provide better targeting and improvement in the management of the disease.

Keywords: inflammation, oxidative stress, histone deacetylase, phosphoinositol 3-kinase, p38 mitogen-activated protein kinase

Definition and prevalence

Chronic obstructive pulmonary disease (COPD) is a disease of the lungs where there is an abnormal chronic inflammatory response. This is associated with remodeling and narrowing of the small airways, which results in airflow limitation and a gradual inexorable decline of lung function that is not fully reversible and is progressive. COPD is usually diagnosed in the clinic by a postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of <70% and a FEV1 of ≥80% predicted. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, COPD severity can be categorized into 4 stages (I–IV) on the basis of FEV1 (Table 1). COPD is considered a preventable and treatable disease in which there may be some significant extrapulmonary effects that may also contribute to the severity of the disease in individual patients.
The abnormal inflammatory response in the lungs of patients with COPD is usually considered to be the result associated with exposure to noxious particles or gases such as those contained in cigarette smoke, which is recognized as the main etiological factor associated with the development of COPD. However, cigarette smoking does not fully explain variations in disease prevalence; therefore, other risk factors are likely to be involved, such as exposure to fossil fuels and environmental traffic pollution. One of the important features of the disease is that the chronic inflammatory response in the lung often persists even when the main exogenous driving factor such as cigarette smoke has been removed. This apparent self-perpetuation of the chronic inflammatory response may contribute to the continuous decline of lung function and subsequent progression of the disease.

COPD is a leading cause of morbidity and mortality. Although the incidence of cigarette smoking in the western world is decreasing, as the population ages, the incidence of COPD is likely to increase before decreasing given the latent nature of the disease. Furthermore, cigarette smoking is increasing in densely populated developing nations such as China, which will further enhance the global burden of the disease. The World Health Organization (WHO) estimated that 3 million people died of COPD in 2005, and there were approximately 210 million people with COPD in 2007. Currently, COPD is the fifth most common cause of mortality worldwide, but total deaths due to the disease are predicted to rise by 30% in the next 10 years. COPD is now predicted to become the third leading cause of death worldwide by around 2030.

### Table 1 GOLD stages of chronic obstructive pulmonary disease severity

<table>
<thead>
<tr>
<th>COPD severity</th>
<th>Characteristics</th>
<th>FEV1/ FVC</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD Stage I</td>
<td>&lt;70%</td>
<td>–</td>
</tr>
<tr>
<td>(mild)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOLD Stage II</td>
<td>&lt;70% &lt;50%–70%</td>
<td></td>
</tr>
<tr>
<td>(moderate)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOLD Stage III</td>
<td>&lt;70% &lt;30%–50%</td>
<td></td>
</tr>
<tr>
<td>(severe)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOLD Stage IV</td>
<td>&lt;70% &lt;30% or &lt;30%–50% with respiratory insufficiency (defined as PaO2 &lt; 60 mmHg and/or PCO2 &lt; 50 mmHg while breathing air at sea level)</td>
<td></td>
</tr>
</tbody>
</table>

**Pathophysiology**

COPD is a complex disease and is often used as an “umbrella” term to incorporate 3 distinct disease processes, chronic bronchitis, emphysema, and small airways disease, which may be present in varying degrees and contribute to the airflow obstruction. It is worth noting that chronic bronchitis is usually defined by the symptoms of cough and sputum production over the winter months, and this usually may or may not be associated with any indices of airflow obstruction. The increased mucus production due to submucosal gland hypertrophy and hyperplasia in chronic bronchitis coupled with the reduction in mucociliary clearance seen in patients with COPD is a major contributing factor in bacterial colonization and infections, which contributes to exacerbations. The destruction of the parenchyma and enlargement of the alveoli and alveolar ducts distal to the terminal bronchioles termed “emphysema” are likely to contribute to airflow limitation because of a loss of the lung elastic recoil.

The degree of airflow limitation (as measured by FEV1) is correlated with the degree of wall thickening of the small airways, providing evidence of a role for small airway remodeling in the airflow obstruction in COPD. The decline of lung function and the severity of the disease correlated with the degree of narrowing of the small airways but not with the degree of emphysema or chronic bronchitis present. This suggests that the narrowing of the small airway may be a predominant factor in the development of airflow limitation in COPD.

The degree of inflammation in the lungs of patients with COPD increases with the severity of the disease. The inflammation is characterized by an accumulation of neutrophils, macrophages, B cells, lymphoid aggregates, and CD8+ T cells, particularly in the small airways. This is likely to represent both innate and adaptive immune responses to the toxic particles and gases. This inflammation is orchestrated by a complex milieu of proinflammatory mediators, including chemokines, such as CCL2, CXCL1, and CXCL8; cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and interferon (IFN)-γ; and proteases, such as neutrophil elastase and metalloproteinase. As the severity of COPD advances, there is an increase in the numbers of B cells, which may indicate an adaptive immune component to the inflammatory response in the later stages of COPD. Autoimmunity may also play a role in COPD, in particular, caused by cigarette smoke-damaged proteins, with autoantibodies, including anti-elastin, antiepithelial, and tobacco anti-idiotypic antibodies, detected in smoking patients with COPD.
Some inflammatory cells also appear to be functionally altered in COPD, which is likely to contribute to the pathogenesis and progression of the disease. In particular, the phagocytic ability of both neutrophils and macrophages is reduced, which is likely to contribute to the ineffective control of bacterial colonization and clearance of dead cells, respectively.\textsuperscript{18–20} Impairment in the clearance of dead and damaged cells is also likely to contribute to the enhancement and chronic nature of the inflammatory response.

**Glucocorticoid treatment in COPD**

The abnormal chronic inflammation in the lung of patients with COPD is widely recognized as a prominent driving force in the progression of the disease. However, no current anti-inflammatory treatments significantly modify the chronic inflammatory response or the decline of lung function.

**Inhaled glucocorticoids**

Although both inhaled and oral glucocorticoids (GCs) are effective at controlling inflammatory lung diseases such as asthma, their effectiveness is substantially less in COPD; therefore, their contribution to the management of stable COPD is limited.\textsuperscript{1,21} Results published from the TOwards a Revolution in COPD Health (TORCH) study of patients with COPD, with a FEV1 of \(< 60\%\), indicated that regular use of inhaled GCs may decrease the rate of decline of lung function.\textsuperscript{22} However, the majority of studies have concluded that the use of regular inhaled GCs has no impact on the long-term progressive decline in FEV1.\textsuperscript{23–26}

Regular treatment with inhaled GCs may reduce the frequency of exacerbations of the disease in patients with severe (GOLD stage III) and very severe (GOLD stage IV) COPD.\textsuperscript{27–29} Regular inhaled GCs may also reduce dyspnea and thereby improve health status.\textsuperscript{30} In addition, withdrawal from inhaled GC treatment can lead to increased rates of exacerbations in some patients.\textsuperscript{31} However, treatment with inhaled GCs increases the risk of pneumonia and does not reduce the overall mortality.\textsuperscript{32–34} Therefore, although the majority of studies show that inhaled GCs have no impact on the progression of the decline of lung function, there is evidence that patients with more advanced (GOLD stage III or IV) COPD and repeated exacerbations may derive some benefit. A number of studies have also shown that a combination of long-acting \(\beta_2\)-agonists (LABAs) and inhaled GCs is more effective than either treatment alone in reducing exacerbation frequency, improving lung function, and improving health status.\textsuperscript{29,30,32,35–38} Results from the TORCH study also indicated that a combination therapy of LABA and inhaled GC may reduce the rate of decline of lung function.\textsuperscript{32} However, similar to the effects of inhaled GC therapy alone, a combination therapy of LABAs and inhaled GCs also increases the likelihood of pneumonia and has no significant effect on overall mortality.\textsuperscript{32}

**Oral GCs**

An early study suggested that short-term GC effects can predict long-term effects of GCs on FEV1; therefore, short-term use of oral GCs (2 weeks) could be recommended to assess if a patient was likely to benefit from long-term use of either inhaled or oral GC therapy.\textsuperscript{39} However, other recent studies indicate that short-term use of oral GCs is a poor predictor of long-term response to inhaled GCs.\textsuperscript{3,26,40} Consequently, GOLD guidelines do not recommend undertaking a therapeutic trial with oral GCs in patients with stage II (moderate), stage III (severe), or stage IV (very severe) COPD who have a poor response to an inhaled bronchodilator.\textsuperscript{1} The short-term response to oral course of prednisolone in terms of increased airway caliber and improved health-related quality of life can be predicted by the presence of sputum eosinophilia.\textsuperscript{41,42}

Oral GCs provide benefit in the treatment of COPD exacerbations with a significant reduction in treatment failure and the need for additional medical treatment and shorter hospital stay.\textsuperscript{43} However, the benefits of oral GCs in the treatment of stable COPD are less evident and convincing given the minimal improvements in lung function and the long-term side effects of oral GC therapy.\textsuperscript{44} Therefore, although inhaled GCs do have some benefits in the treatment of COPD, particularly in advanced disease, their benefits are limited; both inhaled and oral GC therapies provide more benefit in acute exacerbations: the former prevents the exacerbation and the latter reverses it. However, the modest beneficial effect of inhaled GCs on the frequency of exacerbations has been questioned.\textsuperscript{45–47}

**GC insensitivity in COPD**

The limited effectiveness of GC treatment in COPD compared with other inflammatory lung conditions such as asthma has led to the concept that the inflammation in the lung of patients with COPD is relatively GC insensitive.\textsuperscript{21} In addition to having no impact on the decline of lung function, inhaled GCs have little effect on the numbers of inflammatory cell or on the release of proinflammatory mediators in the lungs of patients with COPD.\textsuperscript{38–50} This is reflected \textit{ex vivo} where GCs fail to repress the release of proinflammatory mediators from
alveolar macrophages obtained from the bronchoalveolar lavage from patients with COPD.51

**Development of GC insensitivity in COPD**

**Cellular mechanisms**

The molecular mechanisms that contribute to the development of a relative GC-insensitive inflammatory response in COPD remain unclear. First, there is an inherent variation in GC responsiveness between different cell types and tissues.52 This may relate to the expression of the dominant negative glucocorticoid receptor (GR)β isoform, whose expression correlates with effective GC function in particular cells or tissues.52,53 However, the majority of the cells that make up the lung and the infiltrating inflammatory cells in COPD are largely responsive to GCs. In addition, other inflammatory conditions involving many of these cell types are well controlled. It is therefore unlikely that an intrinsic relative GC unresponsiveness of a particular cell type or of the lung itself can fully account for the reduction of GC insensitivity seen in COPD.

One exception to this is neutrophils, where neutrophilic inflammation is relatively unresponsive to GC-mediated immunosuppression compared with other cell type predominant inflammation.54,55,56 Neutrophils are not only present in stable COPD but are the predominant infiltrating inflammatory cells in exacerbations of the disease, which are also controlled to a lesser extent by GCs.45 Some studies have suggested that this may be due to a relatively high expression of the dominant negative GRβ isoform.53 However, other studies have found low expression of GRβ; therefore, this concept is controversial, and the exact mechanisms behind the reduced effectiveness of GCs on neutrophilic inflammation remains unclear.56 It is also unclear whether the GC insensitivity during exacerbations is an extension of the existing GC insensitivity of stable COPD or if there is an additional unresponsiveness mediated by the acute elevation in neutrophils during the exacerbation.

The levels of GRβ expression have been assessed in COPD, but although the expression of GRα is reduced, there is no apparent change in the expression of GRβ.54,56 It is therefore feasible that a higher level of GRβ to GRα ratio in the lung or inflammatory cells in patients with COPD may impair GRα function enough to contributing to GC insensitivity. However, with very few studies assessing the relative expressions of GRα and GRβ in COPD and importantly, any functional impact by an elevation in the ration of GRβ, it is difficult to assign a role for GRβ in the development of GC insensitivity with any confidence. Impairment of GRα translocation contributes to reduced GC responsiveness in some diseases, such as in a subset of patients with multiple sclerosis where an elevation of expression of heat shock protein 90 (Hsp90) results in increased sequestration of GRα to the cytosol.64 However, although there is evidence for an elevation of Hsp90 expression in COPD, and in some assays, oxidant stress can impair GRα translocation in vitro, currently, there is a lack of any compelling in vivo or translational evidence of a role for impaired GRα translocation in COPD GC responsiveness.59,60

**Genetics**

A number of studies have linked genetic mutations with the development of GC insensitivity.52 In patients with asthma, 11 genes have now been identified, which may discriminate between relative GC-insensitive and GC–sensitive patients with asthma, suggesting that there may be a genetic factor in the development of relatively GC-insensitive asthma.51 A direct link between genetic mutations and the development of relative GC insensitivity in COPD has not been established. However, there is evidence that genetic susceptibility is likely to play a role in the development of COPD. Studies investigating the antioxidant capacity of the lungs of patients with COPD and smokers suggest that subjects that develop COPD have a reduced capacity to elevate their antioxidant defenses, which may, in part, account for the development of COPD in a subset of smokers (~20%) rather than all smokers.62-64 Interestingly, the 213Gly variant of the antioxidant extracellular superoxide dismutase 3 (SOD3), which affects approximately 2% of the population, increases the plasma SOD3 levels 10-fold and has been associated with a protection in smokers to the consequent development of COPD.63,65 Furthermore, given the likely central role for oxidant stress in the development of GC insensitivity (discussed in the following section), the reduced antioxidant capacity is also likely to contribute to the development of a relative GC insensitivity in COPD.

**Oxidative stress**

As the innate or helper T cell type 1 (Th1) inflammatory response is well documented as responding well to GCs, the enhanced and relatively GC-insensitive inflammatory cell present in the lungs of patients with COPD is likely to incorporate an underlying factor. One prominent theory is that an elevation in the oxidant burden in the lungs (termed “oxidative stress”) plays a central role in both the enhancement of the inflammatory response and the development of
Glucocorticoid insensitivity in chronic obstructive pulmonary disease

A central factor in both an oxidant-mediated enhancement of inflammatory responses and development of relative GC insensitivity may be facilitated by a direct alteration in the acetylation–deacetylation balance of the core histone proteins. A central part of GRα function is the recruitment of corepressor complexes containing histone deacetylases (HDACs), which remove acetyl groups from the NH-terminal tails of core histone proteins. These acetyl groups on histone tails confer a “relaxed” transcriptionally open structure to the promoter region of the genes, and their removal results in reassociation of the DNA around the core histones and gene silencing. In vitro studies using small interfering RNA and overexpression models have shown that HDAC-2 is the key in the functional mechanism of GC-mediated or GRα-mediated histone deacetylation and gene repression.

Acutely, oxidative stress reduces HDAC-2 activity with a reduction in HDAC-2 protein expression seen with more chronic oxidant exposures in in vitro and in vivo models. This reduction in HDAC-2 activity and expression is strongly associated with oxidant-mediated covalent modifications, including hyperphosphorylation, nitration, and carbonylation, which impair protein activity and enhance proteasomal degradation. These modifications are mediated by reactive oxygen, including reactive carbonyls and reactive nitrogen species, and by kinase signaling pathways activated by oxidant stress. Although the exact mechanisms and pathways that regulate these modifications remain unclear, recent work has suggested that oxidants modulate HDAC-2 phosphorylation and subsequent ubiquitination followed by proteasomal degradation through a protein kinase CK2α-dependent mechanism.

The acetylation–deacetylation balance of histone is a highly regulated process and central in the control of gene transcription. Therefore, this oxidant-mediated loss of HDAC-2 activity and resulting imbalance in histone acetylation status are likely to contribute to the enhanced inflammatory responses in this disease. In agreement with this, HDAC-2 activity and expression are reduced in the peripheral lungs of patients with COPD, which correlate with disease severity. Furthermore, as HDAC-2 activity is fundamental for functional GRα transrepression of proinflammatory genes, a reduction in its activity and expression is likely to impair GC function and thereby contribute to a reduction in GC responsiveness (Figure 1). Similarly, in models where HDAC-2 activity is compromised, GC function is reduced, and restoration or protection of HDAC-2 activity is correlated with a restoration in GC sensitivity. Therefore, there is strong evidence that the reduction in HDAC-2 activity and expression seen in patients with COPD is likely to be an important factor in the mechanisms of the relative GC insensitivity in this disease. In addition, as there is a reduction in expression of other HDACs in COPD, including HDAC-3, 5, and 8, it must also be considered that the alteration in the expression and/or activity of other HDACs may also play a role in the impairment of GC function. Cigarette smoke exposure results in a reduction of HDAC-1, 2, and 3 in the macrophage cell line, Mono Mac 6 cells, associated with elevated tyrosine nitration and aldehyde adduct formation. However, the roles of these HDACs in the lung and inflammatory cells involved in COPD are poorly understood, and studies are needed to clarify their roles in GR function and in disease.

Kinase signaling

Kinase signaling is integral to the orchestration of the inflammatory response. However, some of these kinase pathways are elevated in COPD and may also play a role in the development of GC insensitivity in the disease. The expression of p38 mitogen-activated protein kinase (MAPK) is elevated in the peripheral lungs and alveolar macrophages in patients with mild or moderate COPD compared with smokers. This study also suggested...
an inverse correlation between the activation of p38 MAPK and the reduction in FEV1 and FEV1/FVC. An elevation of p38 MAPK may be responsible for an increase in phosphorylation of GRα in a manner that results in a reduction of its ligand-binding ability. A negative feedback mechanisms used by GCs to regulate the inhibitory effect of p38 MAPK on GRα in an induction of MAPK phosphatase-1 (MKP-1) expression, which reduced p38 MAPK activity by dephosphorylation (REF). A study looking at patients with severe asthma vs nonsevere asthma found a reduction in the dexamethasone-induced expression (messenger RNA) of MKP-1 and elevation in p38 activity in patients with severe asthma compared with patients with nonsevere asthma. However, no studies have looked at the GC-mediated induction of MKP-1 in COPD, and consequently no links have yet been made between the expression, activity, or signaling of MKP-1 and the reduction in GC responsiveness in COPD, although the potential is clearly explained.

There is also increasing evidence that a plethora of other kinases and signaling pathways, including glycogen synthase kinase-3β, extracellular signal-regulated kinase-1/2, and c-Jun N-terminal kinase, can directly regulate the activity of GRα through phosphorylation and thereafter may also influence its gene specificity.

Oxidant stress also activates various kinase pathways, including the phosphoinositide 3-kinase (PI3K)/Akt pathway through selective activation of the PI3Kδ isoform (Figure 1). Our recent study has shown that the activation of both PI3Kδ and Akt is elevated in macrophages from the peripheral lungs of patients with COPD. Specific inhibition of PI3Kδ/Akt signaling pathway restores and protects both HDAC-2 activity and GC function in oxidant-mediated GC-insensitive models. Similarly, selective inhibition of PI3Kδ/Akt pathway restores the ability of GCs to repress inflammatory mediator expression in patients with COPD comparable to smokers with normal lung function.
However, although the mechanism by which inhibition on PI3Kδ protects GC function appears to be mediated through the protection of HDAC-2 activity, it is also likely to include modulation of other co-repressors, such as Mi-2 and mSin3a. The mechanism by which PI3Kδ affects HDAC-2 activity and GRα function appears to involve oxidant-mediated covalent modifications, including tyrosine nitration and hyperphosphorylation induced by the oxidative stress. However, the mechanisms and pathways that elicited downstream of PI3Kδ/Akt signaling during oxidant stress, which facilitates the modification of HDAC-2 and expression of other corepressors, remain unclear.

**Strategies for overcoming GC insensitivity in COPD**

**Restoration of GC function**

GCs provide an effective treatment for the control of both acute and chronic inflammation in many diseases. Their delivery, side effects, and drug–drug interactions are all well characterized; therefore, the ability to restore the function of GC in COPD is a favorable strategy. The methylxanthine theophylline has been shown to provide a GC “sparing” effect when given at a low concentration with GCs. A low dose of theophylline may also improve the anti-inflammatory action of GC in an exacerbation of COPD. However, the exact mechanism of this GC “sparing” action is unclear. Theophylline is often described as a phosphodiesterase (PDE) inhibitor but is also known to have many “off-target” interactions including gene regulation. Importantly, the concentrations that can achieve this GC sparing are below the concentration at which it targets PDE. This is further complicated by an interesting observation that the binding profile of theophylline is significantly different in cells that have been exposed to oxidative stress and is therefore likely to be different in patients with COPD and those with their higher oxidant burden in lung. Although the exact direct molecular targets of theophylline that confer this GC sparing or enhancing activity remain unresolved, the downstream mechanism involves the restoration of HDAC activity. In addition to theophylline, the curcumin, a polyphenolic natural compound, has also demonstrated an ability to restore GC function in vitro. Similar to theophylline, the curcumin-mediated restoration of GC function is proposed to work through a protection of HDAC-2 expression and activity. However, as with theophylline, curcumin has a seemingly wide and relatively nonspecific action at a range of concentrations including activation and repression of several kinases and transcription factors. Although functionally it has been documented as antioxidant, anti-inflammatory, and GC protective, the precise molecular targets for these specific actions may be difficult to elucidate, and further studies into the precise molecular effectors of its actions are required.

Selective inhibition of PI3Kδ also restores the ability of GCs to repress inflammatory mediator expression, which appears to be through protection and/or restoration of HDAC-2 activity. This similarity between the reported mechanisms may indicate that theophylline may be mediated its action through inhibition of the PI3Kδ pathway, but although theophylline does inhibit various PI3K isoforms at high concentrations, a direct link at a low concentration in oxidant-stressed cells has yet to be made. The PI3Kδ and γ isoforms are also relatively leukocyte specific and are central in the orchestration of both the innate and the adaptive immune responses, including neutrophil recruitment, high-affinity IgE receptor (FcεRI) signaling, and chemokine signaling. Selective PI3Kδ/γ inhibitors have received intense interest from the pharmaceutical industry and are being developed as anti-inflammatory drugs, particularly for allergic disease. Therefore, with selective PI3K isoform inhibitors currently under development, the targeting of PI3Kδ may be preferable to theophylline whose mechanism remains unclear and has no additional anti-inflammatory effect itself (Figure 2).

**Alternative anti-inflammatory agents**

Alternative anti-inflammatory targets have been proposed for COPD. TNF-α is a central mediator in the inflammatory response seen in the lungs of patients with COPD. However, a trial with the anti-TNF-α antibody infliximab determined that there was no benefit in moderate to severe COPD, and this was associated with severe adverse events, particularly cancer and lung infections. Selective p38 MAPKα inhibitors are potent at suppressing the release of proinflammatory mediators in vitro including those closely associated with COPD, such as TNF-α and CXCL8. Selective inhibition of p38 MAPKα also suppresses oxidant-mediated lung inflammation in mice where GCs are not effective, indicating that the functional anti-inflammatory properties of p38 MAPK inhibitors are not adversely affected by oxidant stress. The expression of p38 MAPK is elevated in the lungs of patients with COPD, and the selective inhibitors reduce the expression of inflammatory markers in the blood of patients with COPD. This suggests that selective targeting of p38 MAPK in COPD may provide a potentially effective alternative therapeutic strategy to GCs.
(Figure 2), particularly that it may also enhance the effect of any concomitant GC therapy. However, p38 MAPKα is important in many cell functions, and one major hurdle facing the development of selective p38 MAPKα inhibitors appears to be cytotoxicity.119

Proresolving strategies

A significant driving force behind an enhanced and persistent inflammation may be an inability of the inflammation to resolve and thereby self-regulate. This is likely to be an integral factor in COPD where even after the removal of the exogenous driving force (predominantly, cigarette smoke), the inflammatory response continues. This impairment of inflammatory resolution may be particularly important in the context of GC treatment in COPD.

Although GCs are not effective at repressing neutrophilic inflammation, studies have shown that GCs can significantly impair the rate of constitutive apoptosis of neutrophils.120 This constitutive cell death is an important “safety” feature of neutrophil function, which prevents a prolonged release of toxic and damaging agents, such as superoxide and neutrophil elastase, which may damage otherwise healthy tissue, thereby perpetuating the inflammatory response.121 Controlled cell death termed “apoptosis” is a key feature of neutrophil cell death, as this prevents the release of the toxic and inflammatory contents of the dead cell and also targets the cell for phagocytosis and clearance by macrophages.121–123 The nonphlogistic clearance of apoptotic neutrophils is also considered a central feature in inflammatory resolution, as it triggers a switch in the phenotype of the macrophages from proinflammatory to proresolving with the release of proresolving mediators, such as prostaglandin E2 and IL-10.121,124–126

Macrophage phagocytosis is impaired in COPD, which may be due to the effect of cigarette smoke, and therefore, the rate of the clearance of apoptotic neutrophils is likely to be reduced.127,128 If GC treatment of patients with COPD reflects what is seen in in vitro assays with a delay in neutrophil apoptosis, then the neutrophil may not only be living longer and releasing more inflammatory...
agents but also be fueling the destruction of the lung and inflammatory response by the release of its cellular contents through necrosis due to its defective clearance by resident macrophages. A few studies have looked into inflammatory resolution in COPD, and there is little direct information on the impact of GCs; however, this area may prove to be useful in finding potentially effective and novel anti-inflammatory drugs for COPD.

Interestingly, in addition to their role in initiation of both innate and adaptive immune responses and a potential role in the restoration of GC function, PI3Ks may also play an important role in the resolution of inflammation. The resolution or allergen-induced eosinophilic inflammation is enhanced by inhibition of PI3K by a mechanism involving blockade of Akt activation and enhanced cell apoptosis. Studies using both transgenic mice and selective inhibitors have demonstrated that PI3KB is required for functional Fcγ receptor-mediated macrophage phagocytosis. Therefore, in addition to their anti-inflammatory action, selective PI3K inhibitors may also promote inflammatory resolution and thereby may provide an additional therapeutic benefit. A range of other small-molecule inhibitors that target the rate of neutrophil apoptosis has also been developed. These include inhibitors of cyclin-dependant kinases such as roscovitine, which have recently been shown to promote neutrophil apoptosis and inflammatory resolution in vivo. Therefore, selective inhibitors that promote neutrophil cell death may also provide a therapeutic inflammatory resolution strategy, although the effectiveness of this in the presence of defective clearance must be investigated. Another approach to promoting the resolution of inflammation is the therapeutic use of molecules that mimic the actions of potent endogenous proresolving mediators such as the lipid mediator resolvin E1. Such therapies are currently under development, including the resolvin E1 mimetic (Resolvyx™); however, their potential therapeutic application in COPD has yet to be investigated.

Summary
GCs are not effective at controlling the chronic inflammatory response in COPD. This persistent and abnormal inflammation in the lung increases as the disease progresses. To date, there are no effective treatments to control this persistent inflammatory response and the associated decline of lung function of COPD. This is largely due to a lack of understanding the nature of the inflammatory response in COPD and the impact of key underlying factors such as oxidative stress on this inflammatory response.

It is clear that an effective anti-inflammatory therapy is likely to play a central role in the effective management of the disease in the future. It is therefore critical that we understand the mechanism of the abnormal inflammatory response in COPD, including the defective ability of GC-activated GRα to repress proinflammatory responses. Therapeutic targeting is likely to involve the oxidant-mediated alterations in kinase signaling and protein function, such as p38 MAPK, PI3Kδ, and GRα corepressors including HDAC-2. A more detailed elucidation of these pathways is needed before selected targets can be identified. In addition, agents that can restore GC sensitivity could be developed through an understanding of oxidant stress effects on GRs and signaling pathways. Some of these agents may also confer effective anti-inflammatory effects in COPD themselves. Finally, given the lack of successful anti-inflammatory drugs for COPD, a combination therapy directed in tandem against other aspects of the inflammatory response such as antioxidants and proresolving therapies may prove to be more effective at controlling the inflammation and thereafter halting the decline of both lung function and disease progression.

Acknowledgments
This study was supported by the UK Medical Research Council and Medical Research Scotland (Marwick) and by the UK Medical Research Council and the Wellcome Trust grants (Chung).

Disclosure
The authors report no conflicts of interest in this work.

References


